U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday By Reuters
(Reuters) – U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc (NYSE:) and partner BioNTech SE (NASDAQ:)’s COVID-19 vaccine on Thursday, an agency official said while kicking off the two-day panel discussion on Wednesday.
On Sept 22-23, the CDC’s Advisory Committee on Immunizing Practices (ACIP), will meet to determine which Americans need the third shot and whether it should be approved for use by Food and Drug Administration.
Pfizer asked for the FDA’s approval of the third shot for everyone over 16 years old, but an FDA panel of advisors last Friday stated that there is no evidence to support a shot for people 65 or older. Although the FDA has yet not revealed its plans, it is still working out how to move forward.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.